Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease.
There is currently a need for improved serological tests for the diagnosis and monitoring of Lyme disease, an infection caused by Borrelia burgdorferi. In the present study, we evaluated luciferase immunoprecipitation systems (LIPSs) for use for profiling of the antibody responses to a panel of B. burgdorferi proteins for the diagnosis of Lyme disease. Initially, serum samples from a cohort of patients and controls (n = 46) were used for training and were profiled by the use of 15 different B. burgdorferi antigen constructs. For the patient sera, the antibody responses to several B. burgdorferi antigens, including VlsE, flagellin (FlaB), BmpA, DbpA, and DbpB, indicated that the antigens had high levels of immunoreactivity. However, the best diagnostic performance was achieved with a synthetic protein, designated VOVO, consisting of a repeated antigenic peptide sequence, VlsE-OspC-VlsE-OspC, Analysis of an independent set of serum samples (n = 139) used for validation showed that the VOVO LIPS test had 98% sensitivity (95% confidence interval [CI], 93% to 100%; P < 0.0001) and 100% specificity (95% CI, 94% to 100%; P < 0.0001). Similarly, the C6 peptide enzyme-linked immunosorbent assay (ELISA) also had 98% sensitivity (95% CI, 93% to 100%; P < 0.0001) and 98% specificity (95% CI, 90% to 100%; P < 0.0001). Receiver operating characteristic analysis revealed that the rates of detection of Lyme disease by the LIPS test and the C6 ELISA were not statistically different. However, the VOVO LIPS test displayed a wide dynamic range of antibody detection spanning over 10,000-fold without the need for serum dilution. These results suggest that screening by the LIPS test with VOVO and other B. burgdorferi antigens offers an efficient quantitative approach for evaluation of the antibody responses in patients with Lyme disease.
Burbelo
Peter D
PD
Neurobiology and Pain Therapeutics Section, 49 Convent Drive, Building 49, Room 1C20, NIDCR, NIH, Bethesda, MD 20892-4410, USA. burbelop@nidcr.nih.gov
Issa
Alexandra T
AT
Ching
Kathryn H
KH
Cohen
Jeffrey I
JI
Iadarola
Michael J
MJ
Marques
Adriana
A
D000595:Amino Acid Sequence; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000737:chemistry / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D001426:Bacterial Proteins / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D025065:Borrelia burgdorferi / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D047468:Immunoprecipitation; D008074:Lipoproteins / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008193:Lyme Disease / Q000175:diagnosis* / Q000276:immunology; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology*; D012372:ROC Curve; D012680:Sensitivity and Specificity; D017422:Sequence Analysis, DNA; D013997:Time Factors
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001426:Bacterial Proteins; D008074:Lipoproteins; C079616:OspC protein; D010455:Peptides; C105546:VlsE protein, Borrelia burgdorferi; D008156:Luciferases
J Clin Microbiol. 1998 Dec;36(12):3474-9
9817857
PLoS Negl Trop Dis. 2009;3(5):e438
19436728
Infect Dis Clin North Am. 2008 Jun;22(2):341-60, vii-viii
18452806
J Immunol. 1999 Nov 15;163(10):5566-73
10553085
Virol J. 2009 May 01;6:45
19409090
Curr Drug Targets. 2004 Jan;5(1):1-15
14738215
J Clin Microbiol. 2003 Nov;41(11):4955-60
14605123
Clin Vaccine Immunol. 2008 Jan;15(1):115-9
18003819
J Infect Dis. 2010 Jun 15;201(12):1919-22
20443737
J Infect Dis. 2009 Aug 15;200(4):501-9
19569973
Retrovirology. 2008 Oct 20;5:96
18937847
J Vis Exp. 2009 Oct 07;(32):
19812534
J Clin Microbiol. 2008 Jul;46(7):2298-304
18508942
J Infect Dis. 2008 Aug 1;198(3):444-51
18558872
Eur J Clin Microbiol Infect Dis. 2004 Aug;23(8):615-8
15243815
Clin Vaccine Immunol. 2009 Mar;16(3):366-71
19129469
Nat Med. 2007 Feb;13(2):211-7
17237795
Clin Vaccine Immunol. 2007 Aug;14(8):931-6
17567769
Lancet. 1998 Aug 15;352(9127):557-65
9716075
N Engl J Med. 2001 Jul 12;345(2):115-25
11450660
Clin Diagn Lab Immunol. 2005 Sep;12(9):1069-74
16148173
MMWR Morb Mortal Wkly Rep. 1995 Aug 11;44(31):590-1
7623762
J Infect Dis. 1992 Jun;165(6):1127-32
1583333
J Infect Dis. 2003 Apr 15;187(8):1187-99
12695997
Clin Vaccine Immunol. 2009 May;16(5):621-7
19261774
J Clin Microbiol. 1996 Feb;34(2):237-40
8788993
J Clin Microbiol. 2000 Jul;38(7):2530-5
10878038
J Clin Microbiol. 1999 Dec;37(12):3990-6
10565920
J Biol Chem. 1988 Mar 25;263(9):4323-7
2964447
Biochem Biophys Res Commun. 2007 Jan 26;352(4):889-95
17157815